Regulus Therapeutics (NASDAQ:RGLS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday.
According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “
Several other research analysts have also commented on RGLS. Wedbush reiterated an “outperform” rating and issued a $3.00 target price on shares of Regulus Therapeutics in a research report on Thursday. BMO Capital Markets set a $1.00 price objective on Regulus Therapeutics and gave the company a “hold” rating in a research report on Thursday, March 8th. Finally, B. Riley began coverage on Regulus Therapeutics in a research report on Wednesday, March 28th. They set a “neutral” rating and a $1.00 price objective for the company. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. Regulus Therapeutics has an average rating of “Hold” and an average price target of $1.71.
Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. Regulus Therapeutics had a negative return on equity of 214.48% and a negative net margin of 94,318.05%. research analysts expect that Regulus Therapeutics will post -0.59 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the stock. BVF Inc. IL boosted its position in Regulus Therapeutics by 7.9% during the 4th quarter. BVF Inc. IL now owns 13,974,249 shares of the biopharmaceutical company’s stock valued at $14,533,000 after purchasing an additional 1,025,020 shares during the period. Victory Capital Management Inc. boosted its position in Regulus Therapeutics by 18.2% during the 4th quarter. Victory Capital Management Inc. now owns 327,770 shares of the biopharmaceutical company’s stock valued at $341,000 after purchasing an additional 50,530 shares during the period. Ascend Capital LLC acquired a new position in Regulus Therapeutics during the 4th quarter valued at approximately $1,053,000. Renaissance Technologies LLC boosted its position in Regulus Therapeutics by 215.7% during the 4th quarter. Renaissance Technologies LLC now owns 137,589 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 94,000 shares during the period. Finally, A.R.T. Advisors LLC acquired a new position in Regulus Therapeutics during the 1st quarter valued at approximately $121,000. Institutional investors and hedge funds own 53.15% of the company’s stock.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.